LOS ANGELES, CA (Catholic Online) - The researchers also planned to report Sunday at a cancer conference in Chicago that even more importantly, the treatment seems likely to improve survival. While admitting that it will take more time to know for sure, 65 percent of women who received it were still alive versus 47 percent of those in a comparison group given two standard cancer drugs over a two-year period.

Unfortunately, the margin fell just short of the strict criteria researchers set for stopping the study and declaring the new treatment a winner. Doctors hope the benefit becomes clearer with time. The fact that so many women on the new treatment are still alive, researchers can't determine the average survival for the group.

\"The absolute difference is greater than one year in how long these people live,\" the study\'s leader, Dr. Kimberly Blackwell of Duke University says. \"This is a major step forward.\"

There is a warning to those who suffer from breast cancer patients: the drug is still experimental, and is not available yet. Its backers hope it can reach the market within a year.

The treatment builds on Herceptin, the first gene-targeted therapy for breast cancer, used for about 20 percent of patients whose tumors overproduce a certain protein.

Researchers combined Herceptin with chemotherapy so toxic that it can\'t be given by itself, plus a chemical to keep the two linked until they reach a cancer cell where the poison can be released to kill it.

This double dosage, called T-DM1, is the \"smart bomb,\" although it\'s actually not all that "smart." Herceptin isn\'t a homing device, just a substance that binds to breast cancer cells once it encounters them.

Doctors tested T-DM1 in 991 women with widely spread breast cancer that was getting worse despite treatment with chemotherapy and ordinary Herceptin. Test subjects were given either T-DM1 infusions every three weeks or infusions of Xeloda plus daily Tykerb pills - the only other treatments approved for such cases.

The median time until cancer got worse was nearly 10 months in the women given T-DM1 versus just over 6 months for the others, which is the same magnitude of benefit initially seen with Herceptin, which later proved to improve survival, Blackwell says.

T-DM1 caused fewer side effects than the other drugs did. Some women on T-DM1 had signs of liver damage and low levels of factors that help blood clot, but most did not have the usual problems of chemotherapy.

\"People don\'t lose their hair, they don\'t throw up. They don\'t need nausea medicines, they don\'t need transfusions,\" Blackwell says, who has consulted in the past for Genentech, the study\'s sponsor.

© 2012, Catholic Online. Distributed by NEWS CONSORTIUM.